	US 12,280,082 B2
	Formulation for inhibiting virus replication
Hrishikesh Damle, Bangalore (IN)
Assigned to Shibban Ganju, Oak Brook, IL (US)
Filed by Shibban Krishen Ganju, Oak Brook, IL (US)
Filed on Feb. 4, 2021, as Appl. No. 17/167,380.
Claims priority of application No. 202041034650 (IN), filed on Aug. 12, 2020.
Prior Publication US 2022/0047663 A1, Feb. 17, 2022
Int. Cl. A61K 36/19 (2006.01); A61K 31/40 (2006.01); A61K 36/00 (2006.01); A61K 36/23 (2006.01); A61K 36/81 (2006.01)

CPC A61K 36/19 (2013.01) [A61K 31/40 (2013.01); A61K 36/23 (2013.01); A61K 36/81 (2013.01)]

5 Claims

1. A pharmaceutical formulation for inhibition of SARS-COV-2, comprising:

i. active ingredients consisting of:

200 mg-600 mg of Centella asiatica;

100 mg-400 mg of Withania somnifera;

100 mg-400 mg of Andrographis paniculate; and

ii. inert ingredients consisting essentially of:

1 mg-60 mg of starch;

1 mg-50 mg of magnesium stearate; and

1 mg-50 mg of polyvinylpyrrolidone-K 30 (PVP K 30),

wherein the pharmaceutical formulation is formulated for oral administration.